



1

Millions of patients with NDD have no treatment options

- **This is Aubrey**
 - She was born with a neurodevelopmental disorder (NDD)
 - Epileptic seizures, developmental delays, hospitalisation
 - No anti-seizure medication works for Aubrey
- **Millions of patients worldwide**
 - Prevalence of NDD is comparable to prevalence of depression
 - epilepsy, severe autism, cognitive and movement disorders
- **Historically, minimal funding for NDD drug development**
 - It is not possible to sample live brain cells from patients
 - No animal models have been sufficient to understand NDD in human brain cells




* Photo copyright Tess Foundation.
Read more about Aubrey on Tess Foundation home page: <https://www.tessresearch.org/aubrey/>
NeuroLentech and TESS foundation are collaborating on elucidating mechanisms for SLC13A5 Epilepsy

2

2

New treatments can be found by studying patient-derived cell models



We are sourcing our patient samples from our network of clinical collaborators, where sample donations are ethics-approved, consented and exclusively commercially licensed to Neuroleuntech

3

3

We are building a drug discovery pipeline



We will partner with biopharma to co-develop and out-license assets and patient stratification biomarkers

Supported by technology-access-partnerships

Underserved market for NDD

Historically no suitable cell or animal models have been available to develop new drugs.


Epilepsy drug market: **€18B** annually
(massive AED side effects, 40% refractory to treatment)

Autism & Intellectual Disability
no drugs available
– multi-billion € potential

4

4

Strategy for market entry is via partnering



5

5

Why now?

- Technology for iPSC-derived cell models has been matured and validated extensively for 2D co-culture neuronal models
- Biopharma is seeking blue sky opportunities
- The value of patient-derived cell models is recognised by industry

NDD drug discovery is ripe for breakthrough like Cancer R&D was 15 years ago when patient-derived cancer models became gold standard for preclinical cancer drug discovery.



6

6

We are uniquely positioned to deliver this business

Our management team and founders



Fiona Nielsen
CEO

Driving company growth, fundraising and commercial partnerships with biopharma



Carsten Pfeffer
CSO & Co-founder

Building the platform for generation and analysis of patient-derived brain cells



Christoph Bock
Co-founder and scientific advisor

High resolution genetic and molecular data analysis – machine learning and AI



Gaia Novarino
Co-founder & scientific advisor

NDD expert with global network of clinics with access to patients

7

7

IP and competitive advantage



01 Proprietary platform

- optimised workflows (lab + software)
- technology know-how
- screening assays

01

02 Patient material access

- unique, consented, commercially exclusive
- including clinical data
- Founding team with strong research ties with clinics

02

03 High quality database for AI/ML

- Standardised, curated, comparable and relevant for drug discovery
- NDD patient cell models to validate any predictions


03

8

8


Timeline of milestones

Achievements until start 2023



Launching our business

The bigger we build our biobank and associated data, the more drug discovery projects we will start, the more opportunities to bring new treatments to market



Join our journey

We are seeking investors and collaboration partners who share our vision for creating a World first patient-derived cell model platform for NDD drug discovery.



Contact:

Fiona Nielsen, CEO
fnielsen@neurolentech.com